Published in BMC Infect Dis on July 16, 2009
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One (2014) 1.16
The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One (2015) 0.80
Limited access to HIV prevention in French prisons (ANRS PRI2DE): implications for public health and drug policy. BMC Public Health (2011) 0.80
Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS Soc (2015) 0.80
A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduct J (2016) 0.79
A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC Public Health (2014) 0.78
Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. PLoS One (2016) 0.75
Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croat Med J (2016) 0.75
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS (2005) 13.09
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Substance use and risky sexual behavior for exposure to HIV. Issues in methodology, interpretation, and prevention. Am Psychol (1993) 5.90
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health (2001) 4.57
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA (1994) 3.80
Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70
Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy (2007) 3.52
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health (2003) 3.03
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS (2005) 2.91
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep (1998) 1.92
Social circumstances of initiation of injection drug use and early shooting gallery attendance: implications for HIV intervention among adolescent and young adult injection drug users. J Acquir Immune Defic Syndr (2003) 1.89
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (2006) 1.87
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust (1999) 1.85
Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction (2005) 1.80
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis (2007) 1.70
Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.65
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Gendered power dynamics and HIV risk in drug-using sexual relationships. AIDS Care (2000) 1.51
Risk factors for hepatitis C virus infection among street youths. CMAJ (2001) 1.48
HIV and hepatitis C among injecting drug users. BMJ (1998) 1.41
HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS (2005) 1.40
Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis (2002) 1.36
The HCV Synthesis Project: scope, methodology, and preliminary results. BMC Med Res Methodol (2008) 1.34
Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS (2007) 1.31
Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health (1997) 1.28
Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS (1996) 1.27
Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users. Drug Alcohol Depend (2005) 1.24
Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology (2006) 1.23
Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City. J Urban Health (2004) 1.20
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J Viral Hepat (2008) 1.18
Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav (2007) 1.18
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis (2005) 1.18
Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat (2002) 1.17
Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis (2006) 1.17
Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis (2007) 1.14
Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.11
Crack users' cracked lips: an additional HIV risk factor. Am J Public Health (1993) 1.09
Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis (2007) 1.08
Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect (2004) 1.08
A short questionnaire (IRQ) to assess injecting risk behaviour. Addiction (1998) 1.07
Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications. Soc Sci Med (2006) 1.05
A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs (2004) 1.02
A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J (2006) 1.01
Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis (2007) 1.00
Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect (2006) 0.91
Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J Viral Hepat (2006) 0.90
Factors associated with HIV/AIDS high-risk behaviours among female injection drug users. AIDS Care (2007) 0.90
Ethical issues in substance use intervention. Subst Use Misuse (2004) 0.89
Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data--the ANRS-Coquelicot Study. Subst Use Misuse (2006) 0.83
Single-room occupancy hotels: possible solutions and alternatives. Body Posit (1998) 0.81
Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Interne (Paris) (2002) 0.81
[Life trajectory and risk-taking among women drug users]. Med Sci (Paris) (2008) 0.78
Commentary: Modelling and understanding differences in human immunodeficiency and hepatitis C virus epidemiology in injection drug users. Int J Epidemiol (2003) 0.77
Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis (2010) 3.01
Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis (2012) 2.71
A community-wide outbreak of legionnaires disease linked to industrial cooling towers--how far can contaminated aerosols spread? J Infect Dis (2005) 2.38
Antimicrobial resistance in commensal flora of pig farmers. Emerg Infect Dis (2004) 1.95
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol (2007) 1.87
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med (2010) 1.83
Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction (2005) 1.80
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol (2005) 1.77
Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol (2009) 1.72
Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr (2007) 1.68
Increase of Neisseria gonorrhoeae ciprofloxacin resistance in France in 2001-2003. Sex Transm Dis (2006) 1.60
Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS (2006) 1.58
Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion (2002) 1.53
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol (2010) 1.43
Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS (2006) 1.43
Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey. BMC Public Health (2011) 1.43
Risk factors for leptospirosis in metropolitan France: results of a national case-control study, 1999-2000. Clin Infect Dis (2004) 1.39
Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict (2013) 1.29
VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis (2006) 1.29
Incidence of listeriosis and related mortality among groups at risk of acquiring listeriosis. Clin Infect Dis (2011) 1.26
Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis (2014) 1.25
French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992-2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol (2009) 1.17
Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol (2002) 1.17
Novel human reovirus isolated from children with acute necrotizing encephalopathy. Emerg Infect Dis (2011) 1.14
First identification of HIV-1 groups M and O dual infections in Europe. AIDS (2004) 1.12
Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol (2010) 1.11
Different transmission patterns in the early stages of the influenza A(H1N1)v pandemic: a comparative analysis of 12 European countries. Epidemics (2011) 1.10
Introduction of SARS in France, March-April, 2003. Emerg Infect Dis (2004) 1.10
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Influenza pandemic preparedness in France: modelling the impact of interventions. J Epidemiol Community Health (2006) 1.09
Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis (2007) 1.08
Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis (2009) 1.08
HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS (2016) 1.07
Subtype B human immunodeficiency virus (HIV) type 1 mutant that escapes detection in a fourth-generation immunoassay for HIV infection. J Clin Microbiol (2004) 1.07
Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J Med Virol (2006) 1.07
A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol (2005) 1.06
Prevalence and characteristics of individuals with undiagnosed HIV infection in France: evidence from a survey on hepatitis B and C seroprevalence. J Acquir Immune Defic Syndr (2012) 1.05
Difficulties in diagnosing group o human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol (2008) 1.04
Quantifying transmission of norovirus during an outbreak. Epidemiology (2012) 1.04
Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther (2005) 1.02
HIV prevalence and sexual risk behaviors associated with awareness of HIV status among men who have sex with men in Paris, France. AIDS Behav (2013) 1.02
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother (2008) 1.01
Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats. Neuropsychopharmacology (2011) 1.01
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol (2005) 1.01
Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion (2008) 1.01
Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J Clin Microbiol (2006) 1.00
Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France. PLoS One (2012) 0.99
Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS (2002) 0.99
Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol (2004) 0.99
Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS (2007) 0.99
Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology (2009) 0.98
Burden of influenza, healthcare seeking behaviour and hygiene measures during the A(H1N1)2009 pandemic in France: a population based study. BMC Public Health (2012) 0.97
Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology (2010) 0.97
HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses (2003) 0.96
Impact of AIDS on adult mortality: a morgue-based study in Pointe-Noire, Republic of Congo. AIDS (2005) 0.95
Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry (2013) 0.95
Epidemiology and genetic characterization of hepatitis A virus genotype IIA. J Clin Microbiol (2010) 0.94
Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis (2008) 0.94
Assessing the risk of importing dengue and chikungunya viruses to the European Union. Epidemics (2009) 0.93
Campylobacter antimicrobial drug resistance among humans, broiler chickens, and pigs, France. Emerg Infect Dis (2007) 0.93
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Gene-environment interactions in addictive disorders: epidemiological and methodological aspects. C R Biol (2007) 0.92
Risk factors for acquiring sporadic Campylobacter infection in France: results from a national case-control study. J Infect Dis (2008) 0.91
The role of brief motivational intervention on self-efficacy and abstinence in a cohort of patients with alcohol dependence. Int J Psychiatry Med (2009) 0.91
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
Practical considerations for sensitivity analysis after multiple imputation applied to epidemiological studies with incomplete data. BMC Med Res Methodol (2012) 0.90
An incident case-control study of modes of hepatitis C virus transmission in France. Ann Epidemiol (2007) 0.90
Surveillance of lower respiratory tract infections outbreaks in nursing homes in France. Eur J Epidemiol (2009) 0.89
Genetics of dopamine receptors and drug addiction. Hum Genet (2012) 0.89
Are subjects in treatment trials of panic disorder representative of patients in routine clinical practice? Results from a national sample. J Affect Disord (2012) 0.88
Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety (2012) 0.88
Implications of different residential lead standards on children's blood lead levels in France: predictions based on a national cross-sectional survey. Int J Hyg Environ Health (2013) 0.88
Hepatitis A associated with semidried tomatoes, France, 2010. Emerg Infect Dis (2011) 0.88
Determination of French influenza outbreaks periods between 1985 and 2011 through a web-based Delphi method. BMC Med Inform Decis Mak (2013) 0.87
Chikungunya in Europe. Lancet (2008) 0.86
Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001. Ann Epidemiol (2005) 0.86
The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1. J Virol (2012) 0.85
Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization. J Gen Virol (2012) 0.85
Blood lead levels in the adult population living in France the French Nutrition and Health Survey (ENNS 2006-2007). Environ Int (2011) 0.85
Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG. J Clin Microbiol (2002) 0.84
Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France. Vaccine (2002) 0.84
Performance of an immunoassay at detecting recent infection among reported HIV diagnoses. AIDS (2009) 0.84